Nova Total Current Assets vs Accounts Payable Analysis

EYE Stock

0.15 0.01 6.25%

Nova Eye financial indicator trend analysis is infinitely more than just investigating Nova Eye Medical recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Nova Eye Medical is a good investment. Please check the relationship between Nova Eye Total Current Assets and its Accounts Payable accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Nova Eye Medical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Total Current Assets vs Accounts Payable

Total Current Assets vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Nova Eye Medical Total Current Assets account and Accounts Payable. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Nova Eye's Total Current Assets and Accounts Payable is 0.41. Overlapping area represents the amount of variation of Total Current Assets that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Nova Eye Medical, assuming nothing else is changed. The correlation between historical values of Nova Eye's Total Current Assets and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Assets of Nova Eye Medical are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Total Current Assets i.e., Nova Eye's Total Current Assets and Accounts Payable go up and down completely randomly.

Correlation Coefficient

0.41

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Total Current Assets

The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.

Accounts Payable

An accounting item on the balance sheet that represents Nova Eye obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Nova Eye Medical are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most indicators from Nova Eye's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Nova Eye Medical current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Nova Eye Medical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

At this time, Nova Eye's Selling General Administrative is comparatively stable compared to the past year. Tax Provision is expected to grow at the current pace this year, whereas Issuance Of Capital Stock is likely to drop slightly above 6 M in 2024.

	2022	2023	2024 (projected)
Cost Of Revenue	16.2M	3.1M	3.0M
Research Development	617K	567K	1.1M

Cost Of Revenue Research Development

Nova Eye fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock	Other Current Assets
Total Assets		0.71	0.52	0.82	0.98	0.63	0.82	-0.48	0.62	0.52	0.64	0.32	-0.42	0.64	0.62	0.24	-0.2	0.33	0.64	-0.38	0.84	0.73	0.95	0.66	0.89	-0.07
Short Long Term Debt Total	0.71		0.79	0.92	0.56	0.92	0.33	0.24	0.24	0.46	-0.03	0.31	-0.27	-0.03	0.88	-0.01	-0.37	0.38	0.95	0.3	0.94	0.9	0.48	0.95	0.61	-0.05
Other Current Liab	0.52	0.79		0.71	0.36	0.69	0.15	0.34	0.18	0.18	-0.18	0.08	-0.21	-0.18	0.86	-0.16	-0.43	0.41	0.82	0.42	0.8	0.7	0.3	0.66	0.36	-0.03
Total Current Liabilities	0.82	0.92	0.71		0.69	0.79	0.48	0.05	0.34	0.68	0.15	0.17	-0.36	0.15	0.89	0.03	-0.32	0.14	0.92	0.14	0.98	0.86	0.64	0.94	0.69	-0.13
Total Stockholder Equity	0.98	0.56	0.36	0.69		0.5	0.88	-0.65	0.68	0.44	0.79	0.34	-0.41	0.79	0.45	0.31	-0.13	0.32	0.46	-0.56	0.7	0.61	0.99	0.51	0.88	-0.05
Property Plant And Equipment Net	0.63	0.92	0.69	0.79	0.5		0.31	0.21	0.1	0.3	-0.02	0.51	-0.16	-0.02	0.74	0.11	-0.17	0.55	0.83	0.3	0.82	0.86	0.42	0.82	0.6	-0.13
Current Deferred Revenue	0.82	0.33	0.15	0.48	0.88	0.31		-0.75	0.61	0.28	0.85	0.13	-0.27	0.85	0.24	0.13	-0.11	0.21	0.25	-0.62	0.48	0.33	0.91	0.3	0.78	-0.35
Net Debt	-0.48	0.24	0.34	0.05	-0.65	0.21	-0.75		-0.56	-0.03	-0.98	-0.11	0.15	-0.98	0.33	-0.34	-0.21	-0.04	0.36	0.94	0.07	0.13	-0.71	0.25	-0.49	0.08
Retained Earnings	0.62	0.24	0.18	0.34	0.68	0.1	0.61	-0.56		0.07	0.62	-0.01	-0.43	0.62	0.25	-0.29	-0.62	-0.01	0.23	-0.65	0.35	0.22	0.7	0.27	0.33	0.3
Accounts Payable	0.52	0.46	0.18	0.68	0.44	0.3	0.28	-0.03	0.07		0.13	0.07	-0.38	0.13	0.51	0.27	0.01	-0.21	0.53	0.05	0.61	0.54	0.41	0.57	0.55	-0.03
Cash	0.64	-0.03	-0.18	0.15	0.79	-0.02	0.85	-0.98	0.62	0.13		0.18	-0.2	1.0	-0.15	0.35	0.14	0.13	-0.16	-0.91	0.13	0.05	0.84	-0.05	0.63	-0.1
Non Current Assets Total	0.32	0.31	0.08	0.17	0.34	0.51	0.13	-0.11	-0.01	0.07	0.18		-0.17	0.18	0.05	0.62	0.23	0.68	0.15	-0.15	0.22	0.46	0.23	0.17	0.45	0.19
Non Currrent Assets Other	-0.42	-0.27	-0.21	-0.36	-0.41	-0.16	-0.27	0.15	-0.43	-0.38	-0.2	-0.17		-0.2	-0.2	-0.09	0.3	0.14	-0.33	0.2	-0.35	-0.52	-0.34	-0.37	-0.4	-0.5
Cash And Short Term Investments	0.64	-0.03	-0.18	0.15	0.79	-0.02	0.85	-0.98	0.62	0.13	1.0	0.18	-0.2		-0.15	0.35	0.14	0.13	-0.16	-0.91	0.13	0.05	0.84	-0.05	0.63	-0.1
Net Receivables	0.62	0.88	0.86	0.89	0.45	0.74	0.24	0.33	0.25	0.51	-0.15	0.05	-0.2	-0.15		-0.21	-0.49	0.21	0.96	0.4	0.93	0.75	0.4	0.85	0.43	-0.1
Common Stock Total Equity	0.24	-0.01	-0.16	0.03	0.31	0.11	0.13	-0.34	-0.29	0.27	0.35	0.62	-0.09	0.35	-0.21		0.78	0.37	-0.17	-0.29	0.03	0.25	0.25	-0.11	0.49	0.06
Common Stock Shares Outstanding	-0.2	-0.37	-0.43	-0.32	-0.13	-0.17	-0.11	-0.21	-0.62	0.01	0.14	0.23	0.3	0.14	-0.49	0.78		0.06	-0.49	-0.1	-0.34	-0.16	-0.13	-0.4	0.1	-0.27
Non Current Liabilities Total	0.33	0.38	0.41	0.14	0.32	0.55	0.21	-0.04	-0.01	-0.21	0.13	0.68	0.14	0.13	0.21	0.37	0.06		0.22	0.0	0.28	0.39	0.24	0.08	0.42	0.01
Inventory	0.64	0.95	0.82	0.92	0.46	0.83	0.25	0.36	0.23	0.53	-0.16	0.15	-0.33	-0.16	0.96	-0.17	-0.49	0.22		0.41	0.94	0.85	0.39	0.93	0.5	-0.05
Other Stockholder Equity	-0.38	0.3	0.42	0.14	-0.56	0.3	-0.62	0.94	-0.65	0.05	-0.91	-0.15	0.2	-0.91	0.4	-0.29	-0.1	0.0	0.41		0.16	0.16	-0.62	0.28	-0.33	-0.15
Total Liab	0.84	0.94	0.8	0.98	0.7	0.82	0.48	0.07	0.35	0.61	0.13	0.22	-0.35	0.13	0.93	0.03	-0.34	0.28	0.94	0.16		0.88	0.65	0.9	0.71	-0.1
Property Plant And Equipment Gross	0.73	0.9	0.7	0.86	0.61	0.86	0.33	0.13	0.22	0.54	0.05	0.46	-0.52	0.05	0.75	0.25	-0.16	0.39	0.85	0.16	0.88		0.5	0.85	0.71	0.13
Total Current Assets	0.95	0.48	0.3	0.64	0.99	0.42	0.91	-0.71	0.7	0.41	0.84	0.23	-0.34	0.84	0.4	0.25	-0.13	0.24	0.39	-0.62	0.65	0.5		0.45	0.84	-0.11
Short Term Debt	0.66	0.95	0.66	0.94	0.51	0.82	0.3	0.25	0.27	0.57	-0.05	0.17	-0.37	-0.05	0.85	-0.11	-0.4	0.08	0.93	0.28	0.9	0.85	0.45		0.54	-0.05
Common Stock	0.89	0.61	0.36	0.69	0.88	0.6	0.78	-0.49	0.33	0.55	0.63	0.45	-0.4	0.63	0.43	0.49	0.1	0.42	0.5	-0.33	0.71	0.71	0.84	0.54		-0.17
Other Current Assets	-0.07	-0.05	-0.03	-0.13	-0.05	-0.13	-0.35	0.08	0.3	-0.03	-0.1	0.19	-0.5	-0.1	-0.1	0.06	-0.27	0.01	-0.05	-0.15	-0.1	0.13	-0.11	-0.05	-0.17

Click cells to compare fundamentals

Nova Eye Account Relationship Matchups

Nova Eye fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	116.7M	42.0M	36.6M	30.4M	29.9M	40.5M
Short Long Term Debt Total	3.3M	3.7M	1.9M	1.5M	3.3M	3.2M
Other Current Liab	472K	746K	912K	1.3M	1.6M	2.7M
Total Current Liabilities	14.4M	4.7M	3.9M	6.3M	5.7M	9.4M
Total Stockholder Equity	100.6M	35.3M	30.4M	23.2M	21.3M	29.1M
Property Plant And Equipment Net	2.9M	3.5M	2.9M	2.4M	3.9M	4.4M
Current Deferred Revenue	8.2M	(1.9M)	1.0	(639K)	(734.9K)	(698.1K)
Net Debt	(92.3M)	(14.1M)	(6.1M)	(5.9M)	(2.8M)	(2.7M)
Retained Earnings	24.6M	892K	(6.6M)	(21.9M)	(30.7M)	(29.2M)
Accounts Payable	3.8M	2.0M	2.4M	4.3M	3.6M	2.8M
Cash	95.6M	17.8M	8M	7.4M	6.2M	6.6M
Non Current Assets Total	13.8M	15.7M	21.0M	15.8M	15.1M	13.4M
Non Currrent Assets Other	(6.3M)	(6.9M)	(10.1M)	(10.8M)	4.2M	4.4M
Cash And Short Term Investments	95.6M	17.8M	8M	7.4M	6.2M	6.6M
Net Receivables	3.8M	1.9M	2.0M	1.9M	4.1M	6.4M
Liabilities And Stockholders Equity	116.7M	42.0M	36.6M	30.4M	29.9M	40.5M
Non Current Liabilities Total	1.8M	2.0M	2.4M	892K	2.9M	2.1M
Inventory	2.9M	2.9M	3.5M	3.8M	4.3M	4.1M
Other Stockholder Equity	(102.9M)	(37.6M)	(30.8M)	(1.0)	(0.9)	(0.94)
Total Liab	16.2M	6.7M	6.2M	7.2M	8.6M	11.4M
Property Plant And Equipment Gross	10.4M	13.1M	15.2M	9.2M	10.4M	8.7M
Total Current Assets	102.9M	26.3M	15.6M	14.6M	14.7M	22.8M
Accumulated Other Comprehensive Income	(2.4M)	(2.2M)	(439K)	(87.0K)	(693K)	(658.4K)
Short Term Debt	1.9M	1.9M	544K	639K	480K	456K
Other Current Assets	494K	3.7M	2.0M	1.4M	234K	222.3K
Intangible Assets	10.9M	12.1M	18.0M	13.3M	7.0M	6.8M
Other Assets	7.6M	8.7M	10.9M	4.9M	4.4M	4.2M
Long Term Debt Total	1.4M	1.8M	1.4M	892K	802.8K	1.3M
Property Plant Equipment	2.9M	3.5M	2.9M	2.4M	2.1M	2.0M
Other Liab	1.7M	365K	212K	966K	869.4K	1.0M
Net Tangible Assets	97.2M	31.9M	23.2M	14.7M	13.3M	12.6M
Deferred Long Term Liab	7.5M	8.7M	10.9M	4.9M	4.4M	8.7M
Capital Lease Obligations	1.8M	2.3M	1.9M	1.5M	3.3M	3.5M
Net Invested Capital	102.1M	36.8M	30.4M	23.2M	21.3M	20.3M
Short Long Term Debt	9.0M	14.9M	1.6M	1.4M	1.3M	1.2M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Nova Stock Analysis

When running Nova Eye's price analysis, check to measure Nova Eye's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nova Eye is operating at the current time. Most of Nova Eye's value examination focuses on studying past and present price action to predict the probability of Nova Eye's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nova Eye's price. Additionally, you may evaluate how the addition of Nova Eye to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC